Try our beta test site
84 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND cd20 [TREATMENT] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies
Intervention: Biological: Anti-CD20-CAR-transduced T cells
Study Type: Interventional
Number Enrolled: 45
Study Start: March 2016
2 Recruiting A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Interventions: Biological: PF-05280586;   Biological: MabThera®
Study Type: Interventional
Number Enrolled: 394
Study Start: September 30, 2014
3 Not yet recruiting The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma
Interventions: Drug: R-EPOCH;   Drug: R-CHOP
Study Type: Observational
Number Enrolled: 50
Study Start: March 1, 2017
4 Recruiting A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies
Intervention: Drug: REGN1979 multiple dose levels
Study Type: Interventional
Number Enrolled: 150
Study Start: November 2014
5 Recruiting Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies
Intervention: Drug: T-cell therapy + Rituximab + IL-2
Study Type: Interventional
Number Enrolled: 18
Study Start: December 2014
6 Recruiting Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies
Intervention: Biological: XmAb13676
Study Type: Interventional
Number Enrolled: 66
Study Start: October 2016
7 Not yet recruiting A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
Interventions: Drug: IBI301;   Drug: Rituximab
Study Type: Interventional
Number Enrolled: 140
Study Start: November 2016
8 Not yet recruiting A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
Interventions: Drug: SCT400 plus CHOP;   Drug: Rituximab plus CHOP
Study Type: Interventional
Number Enrolled: 330
Study Start: June 2016
9 Recruiting Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia
Intervention: Drug: Rituximab+mVPDL
Study Type: Interventional
Number Enrolled: 77
Study Start: November 2011
10 Recruiting Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
Intervention: Drug: PREBEN
Study Type: Interventional
Number Enrolled: 84
Study Start: February 2016
11 Recruiting BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
Interventions: Biological: BI-1206 single agent dose escalation phase;   Biological: BI-1206 single agent expansion phase;   Biological: Combination of BI-1206 with Rituximab
Study Type: Interventional
Number Enrolled: 81
Study Start: October 2016
12 Recruiting Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Interventions: Biological: Avelumab;   Biological: Utomilumab;   Biological: Rituximab;   Other: Azacitidine;   Drug: Bendamustine;   Drug: Gemcitabine;   Drug: Oxaliplatin
Study Type: Interventional
Number Enrolled: 500
Study Start: December 16, 2016
13 Not yet recruiting A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
Interventions: Drug: IBI301 plus CHOP;   Drug: Rituximab plus CHOP
Study Type: Interventional
Number Enrolled: 400
Study Start: August 2016
14 Recruiting OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine
Interventions: Drug: Conventional Vincristine;   Drug: Liposomal Vincristine;   Drug: Ricover-scheme rituximab;   Drug: optimised rituximab-schedule
Study Type: Interventional
Number Enrolled: 1152
Study Start: November 2011
15 Recruiting Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
Interventions: Biological: anti-CD20-CAR vector-transduced autologous T cells;   Other: genetically engineered lymphocyte therapy
Study Type: Interventional
Number Enrolled: 50
Study Start: January 2013
16 Recruiting Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
Intervention: Drug: Lenalidomide
Study Type: Interventional
Number Enrolled: 44
Study Start: January 2013
17 Not yet recruiting Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Gemcitabine;   Drug: Dexamethasone;   Drug: Cisplatin
Study Type: Interventional
Number Enrolled: 30
Study Start: May 2016
18 Recruiting Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Interventions: Drug: EPOCH;   Biological: Rituximab
Study Type: Interventional
Number Enrolled: 348
Study Start: April 30, 1993
19 Recruiting Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
Interventions: Biological: ACTR087;   Biological: rituximab
Study Type: Interventional
Number Enrolled: 54
Study Start: August 2016
20 Recruiting Treatment for Advanced B-Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: IT Cytarabine
Study Type: Interventional
Number Enrolled: 24
Study Start: January 2013

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.